Top Story

Eyes with severe ocular surface disease at risk for KPro-related melt complications

July 26, 2016

Patients with severe ocular surface disease who underwent implantation of a Boston type 1 keratoprosthesis had a greater risk of developing corneal melts, leaks and extrusions, according to a study.

The retrospective study included 128 eyes of 110 patients who underwent Boston type 1 keratoprosthesis (KPro) implantation at the Cincinnati Eye Institute between 2004 and 2010. Mean follow-up time was 29 months.

CommentaryFrom OSN Europe

Innovative approaches may reduce carbon footprint and environmental impact of surgery

Ocular Surgery News Europe Edition, July 2016
Richard B. Packard, MD, FRCS, FRCOphth
In the cover story on the high carbon footprint of cataract surgery as performed in the developed world, we are made aware of a growing problem for the planet. It…
Cover StoryFrom OSN Europe

High carbon footprint of cataract surgery raises awareness of need for more sustainable practices in operating rooms

Ocular Surgery News Europe Edition, July 2016
Health care procedures are a large contributor to carbon emissions throughout the world. Presently, surgeons and health care organizations are analyzing the effects of…

Publication Exclusive: By YOs for YOs: European Meeting of Young Ophthalmologists more than doubles past attendance

July 26, 2016
The 2nd European Meeting of Young Ophthalmologists took place in Oviedo, Spain, in June, and it was a truly remarkable event. From tailored educational sessions to…

July’s top five FDA news stories in ophthalmology

July 26, 2016
July’s hot topics in ophthalmology ranged from long-awaited FDA approvals including Shire’s lifitegrast ophthalmic solution for dry eye disease to…
More News Headlines »
Original Article

Specialty Practice and Cost Considerations in the Management of Uveitis Associated With Juvenile Idiopathic Arthritis

Journal of Pediatric Ophthalmology and Strabismus, July/August 2016, Volume 53 Issue 4
To evaluate whether cost, prior insurance authorization concerns, and subspecialty practice influence therapeutic…
More »

Clinical Trials in Diabetic Retinopathy

This activity is supported by educational grants from Allergan, Inc.; Genentech, Inc.; and Regeneron Pharmaceuticals, Inc.

The advent of intravitreal therapies to treat retinal diseases has revolutionized the management of retinal pathology…
More »
Highlights from ASCRS

Highlights from ASCRS

Meeting News Coverage

VIDEO: Speaker gives update on infectious uveitis

July 23, 2016
More »